Prescription Drug Patents: Balancing Innovation, Access, and Affordability

Priti Krishtel, J.D., is co-founder and co-executive director of I-MAK. Krishtel is a 15-year veteran of the global access to medicines movement. A graduate of the New York University School of Law, Krishtel worked as a lawyer in the U.S. and Switzerland before joining the Indian NGO Lawyers Collective in 2003. While there, she worked to educate and organize policymakers, media, women’s, children’s and LGBTQ rights groups, and communities living in poverty. That formative, grassroots work was instrumental to Krishtel, who would work alongside fellow activists to lead the access to medicines movement to a pivotal moment in treatment access history: the passage of a health-friendly patent law. This and her subsequent work challenging unjustified patents made I-MAK, which she co-founded in 2006, a recognized global force in the access to medicines movement. As co-executive director of I-MAK, she continues to work alongside patients, advocacy organization, and local activists in Argentina, Brazil, Thailand, Ukraine, and elsewhere to ensure that civil society is recognized as a catalytic force to increase treatment access. Krishtel has never strayed from her roots as a committed campaigner for justice, a community organizer, and a relentless advocate for patients. Krishtel is a frequent speaker at national and international events, and her leadership has been recognized by Echoing Green, PopTech!, Asia Society, The King Baudouin Foundation, and others. She has been featured in Entrepreneur, CNN, The New York Times, Bloomberg, CNBC, The Wall Street Journal, The Hill, and Reuters.

Genia Long, MPP, is a senior advisor at Analysis Group, a leading economic consulting firm, where she focuses on the economics and business strategy of innovation, with an emphasis on the life sciences.  She has assisted executives in addressing mission-critical research and development, market strategy, and financial and business planning challenges, including the impacts of policy and competitive change on the economics of innovation, across all major therapeutic areas. Her clients span biopharmaceutical and medical device manufacturers, technology and service providers, venture capital, trade organizations, and provider organizations, including academic medical centers, specialty and general hospitals, and clinical, research and product marketing joint ventures. Her work has been published in Health Affairs, the Journal of Medical Economics, Expert Opinion on Therapeutic Patents, Expert Reviews in Clinical Pharmacology, Seton Hall Law Journal, Journal of Health Politics, Policy and Law, Nature Reviews Drug Discovery, and other venues.

Ed Silverman, M.A., is senior writer and Pharmalot columnist at STAT. Silverman has covered the pharmaceutical industry for two decades. He previously worked at The Wall Street Journal, The Star-Ledger of New Jersey, and New York Newsday, among other publications. He won the Gerald Loeb Award for business and financial journalism in 2018 for his Pharmalot View columns. Along with several former Wall Street Journal colleagues, Silverman was a Pulitzer Prize finalist in explanatory journalism for a series of stories on prescription pricing. He earned an accounting degree from Binghamton University and a master’s in journalism from New York University.



Sarah J. Dash, MPH, is the president and chief executive officer at the Alliance for Health Policy. She drives the mission and vision of the Alliance, as well as advances and maintains the reputation of the organization as the leading nonpartisan resource for policymakers and health leaders in an evolving health policy environment. Sarah joined the Alliance in 2014 as the vice president for policy and became president and CEO in May 2017. Sarah has long been an influential force in shaping health policy, having served as a senior aide on Capitol Hill and as a member of the research faculty at the Georgetown University Health Policy Institute’s Center on Health Insurance Reforms. Sarah holds a master’s degree in public health from the Yale School of Public Health and a bachelor’s degree in chemistry and literature from MIT. Sarah also holds an Executive Certificate in Nonprofit Management from Georgetown University.